stillwork
Peptide

Semaglutide

The satiety signal amplifier

A GLP-1 receptor agonist that mimics the incretin hormone to reduce appetite and improve metabolic health. Provides significant weight loss effects.

Mechanisms

  • GLP-1 receptor agonism
  • Appetite suppression
  • Insulin sensitization
  • Gastric emptying delay

Dosing

Typical dose

0.25–2.4mg

Timing

Weekly subcutaneous injection. Gradual dose titration over months recommended.

Synergies

Cagrilintide

Semaglutide and Cagrilintide target different satiety pathways for enhanced weight loss

Strong
Tirzepatide

Semaglutide and Tirzepatide both support metabolic health (not typically combined)

Mild

Interactions

Tirzepatide

Semaglutide and Tirzepatide should not be combined - overlapping GLP-1 mechanisms

Avoid
Retatrutide

Semaglutide and Retatrutide should not be combined - overlapping mechanisms

Avoid
Mazdutide

Semaglutide and Mazdutide have overlapping GLP-1 activity

Avoid
Cagrilintide

Cagrilintide combined with Semaglutide requires careful dosing

Caution

Research

RCT2021

Once-weekly semaglutide in adults with overweight or obesity (STEP 1)

Wilding JP et al·NEJM

Semaglutide 2.4mg weekly resulted in 14.9% mean weight loss vs 2.4% with placebo at 68 weeks